Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Infanrix Hexa and Rotarix

GlaxoSmithKline1 site in 1 country230 target enrollmentJuly 3, 2007

ConditionsInfections, Streptococcal Streptococcus Pneumoniae Vaccines

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Infections, Streptococcal
Sponsor: GlaxoSmithKline
Enrollment: 230
Locations: 1
Primary Endpoint: Antibody Concentrations Against Protein D
Status: Completed
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to assess the immunogenicity in terms of antibody response and the safety/reactogenicity in terms of solicited and unsolicited symptoms and serious adverse events following primary vaccination of Mexican infants with pneumococcal conjugate vaccine GSK 1024850A co-administered with a diphtheria, tetanus, acellular pertussis (DTPa)-combined vaccine (Infanrix hexa) and rotavirus vaccine (Rotarix) in children during the first 6 months of age.

Detailed Description

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Registry

clinicaltrials.gov

Start Date

July 3, 2007

End Date

March 31, 2008

Last Updated

6 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

GlaxoSmithKline

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Male or female subjects between and including 6-12 weeks of age at the time of the first vaccination.
•Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.
•Written informed consent obtained from the parent or guardian of the subject.
•Free of obvious health problems as established by medical history and clinical examination before entering into the study.
•Born after a gestation period of 36 to 42 weeks inclusive.

Exclusion Criteria

•Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
•Planned administration/administration of a vaccine not foreseen by the study protocol during the period starting one month before each dose of vaccines and ending 7 days after dose 1 and dose 2 and one month after dose
•Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
•Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth.
•A family history of congenital or hereditary immunodeficiency.
•Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.
•Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
•Previous vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, rotavirus and/or Streptococcus pneumoniae; with the exception of vaccines where the first dose may be given at birth within the first two weeks of life according to national recommendations (e.g. Hepatitis B and BCG).
•History of, or intercurrent, diphtheria, tetanus, pertussis, polio, hepatitis B and Haemophilus influenzae type b disease.
•Gastroenteritis within 7 days preceding the study vaccine administration (warrants deferral of the vaccination).

Outcomes

Primary Outcomes

Antibody Concentrations Against Protein D

Time Frame: One month after the administration of the 3rd vaccine dose i.e. Month 5

Concentrations were given as geometric mean concentration (GMC) expressed as enzyme-linked immuno-sorbent assay (ELISA) units per milliliter.

Antibody Concentrations Against Pneumococcal Vaccine Serotypes

Time Frame: One month after the administration of the 3rd vaccine dose i.e. Month 5

Concentrations were expressed as geometric mean concentration (GMC). The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.

Secondary Outcomes

Number of Subjects Seropositive Against Cross-reactive Pneumococcal Serotypes(One month after the administration of the 3rd vaccine dose i.e. Month 5)
Number of Subjects Seropositive for Opsonic Titer Against Cross-reactive Pneumococcal Serotypes(One month after the administration of the 3rd vaccine dose i.e. Month 5)
Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)(Within 4 days following any vaccine dose)
Number of Subjects Reporting Any Unsolicited AEs(Within 31 days after any vaccine dose)
Number of Subjects Reporting Any Serious Adverse Events (SAEs)(Up to Month 5)
Number of Subjects With Anti-pneumococcal Vaccine Serotypes Antibody Concentrations Greater Than or Equal to 0.2 Microgram Per Milliliter(One month after the administration of the 3rd vaccine dose i.e. Month 5)
Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes(One month after the administration of the 3rd vaccine dose i.e. Month 5)
Number of Subjects Seropositive Against Vaccine Pneumococcal Serotypes(One month after the administration of the 3rd vaccine dose i.e. Month 5)
Number of Subjects Seropositive for Opsonic Titer Against Vaccine Pneumococcal Serotypes(One month after the administration of the 3rd vaccine dose i.e. Month 5)
Number of Subjects Seropositive for Anti-Protein D Antibodies(One month after the administration of the 3rd vaccine dose i.e. Month 5)
Opsonophagocytic Titer Against Pneumococcal Cross-reactive Serotypes(One month after the administration of the 3rd vaccine dose i.e. Month 5)
Opsonophagocytic Titer Against Pneumococcal Vaccine Serotypes(One month after the administration of the 3rd vaccine dose i.e. Month 5)
Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs(Within 4 days following any vaccine dose)